Novartis Ag

Apros Therapeutics, Inc.

Nexys Therapeutics, Inc.

Other

Glaxosmithkline Biologicals Sa

Merck Canada Inc.

Merck Sharp + Dohme Corp.

Actelion Pharmaceuticals Ltd

Irm LLC

U.S. Army Medical Research and Materiel Command

Tom Yao-Hsiang Wu

Timothy Z Hoffman

Yongkai Li

Alex Cortez

Xiaoyue Zhang

Yefen Zou

Daniel Dube

Jianfeng Pan

Michel Gallant

Sebastien Laliberte

Qihui Jin

Helene Juteau

Manmohan Singh

Erich L Grimm

Patrick Roy

Shailaja Kasibhatla

Patrick Lacombe

Renee Aspiotis

Kathy Yue

Andrew T Miller

Tao Jiang

Yun He

Rejean Fortin

Tetsuo Uno

Xing Wang

Gillis Otten

Bernhard Hubert Geierstanger

Badry Bursulaya

Baogen Wu

Nicholas M Valiante

Michael P Cooke

Austin Chen

Dwight Macdonald

Kelli L Kuhen

David Archer Ellis

Daniel J McKay

Pranab Mishra

D Bruce MacKay

Tingting Mo

Daniel McKay

Austin Chih-Yu Chen

David A G Skibinksi

Pierre-Andre Fournier

Louis-Charles Campeau

Jeremy Peter Scott

Nadine Bremeyer

Porino Va

Travis K Warren

Erich I Grimm

Sina Bavari

David A G Skibinski

Nicholas Valiante

David Skibinski

Timothy Hoffman

David Ag Skibinski

The present invention relates to pharmaceutical compounds of Formula (I): as further described herein, and pharmaceutical compositions containing such compounds, as well as methods of using these compounds to modulate the activity of aryl hydrocarbon receptor (AhR) and to treat conditions comprising inflammation inside the intestinal tract and certain disorders of the central nervous system affected by the gut-brain axis, including IBD, ulcerative colitis, Crohn's disease, Huntington's disease, and multiple sclerosis.

Aryl hydrocarbon receptor agonists and uses thereof

The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder associated with TGFβR1 activity, such as a cancer or fibrosis. The invention provides compounds of Formula (I) and Formula (II) as further described herein having an acidic moiety that enhances tissue specificity for targeted tissues and organs. The invention includes pharmaceutical compositions, pharmaceutical combinations, and methods of use of these compounds for treating conditions including cancer or fibrosis.

(Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer

The invention provided herein includes pharmaceutical compositions comprising a TLR7 agonist having the structure of Formula (A), aluminum-containing particles, and one or more pharmaceutically acceptable excipient. The invention further provides the use of such compositions in the treatment of solid tumors either alone or in combination with one or more additional pharmaceutical compositions.

Compounds and compositions for treating solid tumors by intratumoral administration

The present disclosure relates to a class of pyrimidine derivatives having immunomodulating properties that act via TLR7 which are useful in the treatment of viral infections and cancers. One aspect of the present disclosure relates to a compound represented by Formula 1: 

Substituted pyrimidines containing acidic groups as TLR7 modulators

Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies.

Antibody conjugates comprising toll-like receptor agonist

The present disclosure relates to a class of pyrimidine derivatives having immunomodulating properties that act via TLR7 which are useful in the treatment of lung cancer and other respiratory conditions. The present disclosure specifically discloses compounds having the structuree of Formula (I), and pharmaceutically acceptable salts thereof. 

Pyrimidine compounds containing acidic groups

The invention provides compounds of Formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity. 

Compounds and compositions as toll-like receptor 7 agonists

Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminum salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

Adsorption of immunopotentiators to insoluble metal salts

The invention provides a compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.

The present invention generally relates to compositions comprising benzonapthyridine small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject that has had pre- or post-exposure to a pathogen such as hemorrhagic fever virus. Also provided are methods of preparing and using the SMIP compositions of the invention.

Benzonapthyridine compositions and uses thereof

Growing community of inventors

San Diego, CA, United States of America

Tom Yao-Hsiang Wu